Monoclonal antibody (MAb) 11E10 recognizes the Shiga toxin type 2 (Stx2) A 1 subunit. The binding of 11E10 to Stx2 neutralizes both the cytotoxic and lethal activities of Stx2, but the MAb does not bind to or neutralize Stx1 despite the 61% identity and 75% similarity in the amino acids of the A 1 fragments. In this study, we sought to identify the segment or segments on Stx2 that constitute the 11E10 epitope and to determine how recognition of that region by 11E10 leads to inactivation of the toxin. Toward those objectives, we generated a set of chimeric Stx1/Stx2 molecules and then evaluated the capacity of 11E10 to recognize those hybrid toxins by Western blot analyses and to neutralize them in Vero cell cytotoxicity assays. We also compared the amino acid sequences and crystal structures of Stx1 and Stx2 for stretches of dissimilarity that might predict a binding epitope on Stx2 for 11E10. Through these assessments, we concluded that the 11E10 epitope is comprised of three noncontiguous regions surrounding the Stx2 active site. To determine how 11E10 neutralizes Stx2, we examined the capacity of 11E10/Stx2 complexes to target ribosomes. We found that the binding of 11E10 to Stx2 prevented the toxin from inhibiting protein synthesis in an in vitro assay but also altered the overall cellular distribution of Stx2 in Vero cells. We propose that the binding of MAb 11E10 to Stx2 neutralizes the effects of the toxin by preventing the toxin from reaching and/or inactivating the ribosomes.
Stx2c, Stx2d, Stx2d-activatable (Stx2d act ), Stx2e, and Stx2f (reviewed in reference 18).
Stxs are complex holotoxins with a stoichiometry of five identical binding (B) subunits and a single active (A) domain. These AB 5 molecules are potent cytotoxins with an N-glycosidase activity that stops protein synthesis by inactivation of the 60S ribosome (6) ; this activity eventually leads to eukaryotic cell death. The ϳ32-kDa A subunit contains the enzymatic activity of the toxin with the active site glutamic acid residue at position 167. The A subunit is asymmetrically cleaved by trypsin or furin into an enzymatically active ϳ28-kDa A 1 fragment and an ϳ4-kDa A 2 peptide. The A 2 peptide remains linked to the large enzymatic domain through a disulfide bond and is encircled by the five identical B subunits of ϳ7.7 kDa. The B subunits of the Stxs typically bind to the eukaryotic glycolipid receptor globotriaosylceramide (Gb 3 ), also known as CD77. The mature A and B subunits of Stx1 and Stx2 are approximately 68 and 73% similar at the amino acid level. The crystal structures of Stx and Stx2 have been resolved, and the two structures are remarkably similar (7, 8) . Nevertheless, there are some features of these three-dimensional models that differ (summarized in reference 8).
Currently, there are no Food and Drug Administrationapproved therapies in the United States to treat STEC infections. However, our research group is one of several that investigate passive immunization strategies to neutralize the Stxs associated with STEC infections (3, 4, 10, 13, 19, 20) . Our passive immunization strategy is based on murine monoclonal antibodies (MAbs) developed in this laboratory that specifi-cally bind to and neutralize Stx/Stx1 or Stx2 (21, 28) . The MAb 11E10 was generated by immunization of BALB/c mice with Stx2 turned into a toxoid ("toxoided") by treatment with formaldehyde (21) . MAb 11E10 specifically recognizes the A 1 fragment of Stx2 and neutralizes Stx2 for Vero cells and mice but does not bind to or neutralize Stx/Stx1 (21) . The murine MAb 11E10 was modified to contain a human constant region to reduce the potential for an antibody recipient to generate an antimouse antibody response (4) . This human-mouse chimeric antibody, called c␣Stx2, successfully underwent phase I clinical testing (3) . In this report, we define the epitope on the A subunit of Stx2 recognized by the murine MAb 11E10 (and, therefore, also by c␣Stx2) and present evidence that the MAb blocks the enzymatic action of the toxin in vitro and also alters toxin trafficking in Vero cells.
MATERIALS AND METHODS
Bacterial strains, plasmids, purified Stx1 and Stx2, and MAbs 11E10 and 13C4. Bacteria were grown in Luria-Bertani (LB) broth or on LB agar (Becton Dickinson and Company, Sparks, MD) supplemented with 100 g/ml of ampicillin as needed for selection of recombinant plasmids. Bacterial strains used in this study are listed in Table 1 . Stx1 and Stx2 were purified by affinity chromatography as described previously (17) , and the MAbs 11E10, 11F11 (specific for Stx2) (21) , and 13C4 (specific for Stx1) (28) were produced in this laboratory and deposited with BEI Resources (Manassas, VA).
Construction of chimeric toxin plasmids.
Six chimeric toxin genes that contained portions of both stxA 1 and stxA 2 were generated by PCR with the splicing by overlap extension protocol (9) , and the PCR products were ligated into pBluescript II KS(Ϫ) (Stratagene, La Jolla, CA). A list of all plasmids used in this study is given in Table 1 . The chimeric toxin genes contained the native promoters and Shine-Dalgarno sequences, and the levels of toxin expression from five of the clones were sufficient under those conditions. To increase the level of expression of the A subunit in one clone, an optimized Shine-Dalgarno sequence was added upstream of stxA 2 , and the toxin gene was inserted into the pTrcHis2 C expression vector (Invitrogen, Carlsbad, CA). All primers used in this study are listed in Table 2 . The DNA sequence of each construct created for this study was confirmed prior to use.
Five additional His-tagged chimeric toxins were generated from an stx 1 clone that contained six histidine codons immediately downstream of the B gene. The toxins produced by these chimeras contain one, two, or three regions from the Stx2 A subunit (hereafter referred to as regions A, B, and C) that comprise the putative MAb 11E10 epitope in place of the comparable sequence in Stx1 (see Fig. 2A ). Regions A, B, and C refer to amino acids 42 to 49, 96 to 100, and 244 to 259, respectively, of the Stx2 A subunit. The five chimeric toxins made were named Stx1 ϩA, Stx1 ϩAB, Stx1 ϩAC, Stx1 ϩBC, and Stx1 ϩABC.
Generation and purification of partially toxoided Stx1 ؉ABC. The cytotoxicity of the Stx1 ϩABC toxin for Vero cells was reduced 10,000-fold by changing the tyrosine residue at position 77 of the A subunit to a serine residue by the splicing by overlap extension protocol. This 4-log reduction in cytotoxicity after the Y77S mutation was introduced is similar to that previously reported for the Y77S mutation in Stx1 (2) .
The Stx1 ϩABC toxoid was purified with a nickel affinity column as previously described (26) . The concentration of the toxoid was determined by bicinchoninic acid assay (Pierce, Rockford, IL). A silver stain of a sodium dodecyl sulfate clone was generated by PCR from E. coli EH250 with primers 2DF and 2DR (22) . The PCR product was ligated into the expression vector pTrcHis2 C. That stx 2c and stx 2d were amplified correctly was confirmed by sequence analyses.
Western blot analyses. Purified Stx1, Stx2, or sonic lysates of bacteria that expressed chimeric Stx1/Stx2 toxins were subjected to SDS-polyacrylamide gel (26) . The concentrations of the A subunits in sonic lysates that contained Stx1, Stx2, or the chimeric toxins were estimated as follows. First, the specific dilutions of rabbit anti-Stx1 and anti-Stx2 rabbit polyclonal antibodies (PAbs) that detected the purified A subunits from Stx1 or Stx2, respectively, to relatively equivalent levels were determined through the use of NIH Image J software (http://rsb.info.nih.gov/nih-image). Second, the chimera-containing sonic lysates were separated by SDS-PAGE; the resulting gels were then transferred to nitrocellulose, and those blots were then probed with a mixture of rabbit anti-Stx1 and anti-Stx2 rabbit PAbs diluted as determined above. Third, the bands that corresponded to the chimeric A subunits in each lane were quantified with the NIH Image J program to determine the toxin concentration in each lysate sample. Fourth, two additional polyacrylamide gels were loaded with purified Stx1, Stx2, or samples of the chimera-containing lysates normalized to contain equivalent concentrations (as determined from step 3). The toxin preparations were then subjected to SDS-PAGE followed by Western blot analysis with a mixture of rabbit anti-Stx1 and/or rabbit anti-Stx2 PAbs or MAb 11E10. The secondary antibodies used in these Western blots were goat antirabbit immunoglobulin G (IgG) conjugated to horseradish peroxidase (Bio-Rad, Hercules, CA) at a dilution of 1:15,000 or goat anti-mouse IgG conjugated to horseradish peroxidase (Bio-Rad, Hercules, CA) at a dilution of 1:3,000, as appropriate. The bound secondary antibodies were detected by chemiluminescence with the ECL-Plus Western blotting detection kit (Amersham Bioscience, Little Chalfont, Buckinghamshire, England). Western blots were also performed on sonic lysates of clones that expressed Stx2, Stx2c, Stx2d, Stx2d act , or Stx2e. First, the concentration of the A subunits from these toxin samples was determined as described above, except that only rabbit anti-Stx2 PAb was used as a probe. Then two additional polyacrylamide gels were loaded with equivalent quantities of the normalized samples, and Western blots were conducted with either rabbit anti-Stx2 PAb or MAb 11E10 as the primary antibody. The secondary antibodies and method of detection were the same as described above.
In vitro neutralization assays on Vero cells. In vitro neutralization assays of sonic lysates from bacteria that contained Stx1, Stx2, the chimeric Stx1/Stx2 toxins, Stx2c, Stx2d, Stx2d act , or Stx2e were carried out with 11E10 on Vero cells (ATCC, Manassas, VA) as described previously (14, 26) . MAb 11E10 neutralized Stx2 such that only 35% of the wild-type toxic activity remained. To make it easier to compare the percent neutralization levels of the toxin derivatives by MAb 11E10, the data were then normalized such that the amount of neutralization of Stx2 by 11E10 was set to 100% and the neutralization levels of the other toxins were calculated relative to that of Stx2.
Immunization and challenge of mice. Preimmune sera were collected from CD-1 male mice that weighed 14 to 16 g (Charles River Laboratories, Boston, MA). These serum samples were used in enzyme-linked immunosorbent assays to determine if the mice had preexisting titers of antibodies to Stx1 or Stx2. None of the mice showed an immune response to either toxin at the start of the study. The mice were then divided into two groups: a sham-inoculated group (hereafter called the negative control group) and a group that was immunized with the chimeric toxoid. Mice in the negative control group were immunized intraperitoneally (i.p.) with a mixture of phosphate-buffered saline (PBS) and TiterMax, a water-in-oil adjuvant (TiterMax, USA, Inc., Norcross, GA). The second group of mice was immunized i.p. with 1 g of toxoid mixed with TiterMax. The mice were boosted at 3-week intervals for a total of four boosts. Two weeks after the last boost, five negative control mice and five toxoid-immunized mice were challenged i.p. with 10 times the 50% lethal dose (LD 50 ) of Stx1 (1,250 ng), and 29 negative control mice and 34 toxoid-immunized mice were challenged with 5 LD 50 s of Stx2 (5 ng).
In vitro protein synthesis inhibition assays. Rabbit reticulocyte lysate, firefly luciferase mRNA, and luciferin substrate were purchased from Promega Corporation (Madison, WI). Stx2 (4 ng/l) was combined with an equal volume of antibody (at 4 or 40 ng/l), and 1 l of the toxin-antibody mixture was combined with 9 l reticulocyte lysate. The mixture was incubated at 30°C to allow toxin to inactivate ribosomes in the lysate. After 1 h, an aliquot of luciferase mRNA and amino acids that had been heated to 70°C for 2 min was added, and the solution was incubated for an additional 90 min to allow the in vitro protein synthesis to proceed. All assays were done in triplicate. Luciferase activity was measured by adding 1 l of the lysate mixture to 20 l of luciferin substrate in clear 96-well plates (Fisher Scientific, Pittsburgh, PA). Bioluminescent light emission was detected with a Kodak Image Station 440CF in a 10-min exposure. Luminescent signal was analyzed by summation of total signal intensity within a circular area that corresponded to a single well.
Localization of 11E10 in intoxicated cells. Vero cells were seeded in eight-well tissue culture slides (Thermo Fisher Scientific, Rochester, NY) at a concentration of 1 ϫ 10 5 cells/ml and allowed to adhere for 24 h at 37°C in an atmosphere of 5% CO 2 . Stx2 (0.2 ml of 10 ng/ml) was mixed with 10 ng of purified MAb 11E10 or with PBS as a negative control. The antibody-toxin or PBS-toxin solutions were incubated with Vero cells for 6 h, and then the cells were fixed with buffered formalin (Formalde-Fresh; Fisher Scientific, Pittsburgh, PA) and permeabilized with 0.001% Triton X-100 (Pierce, Rockford, IL) in PBS. All immunostaining procedures were done in PBS with 3% bovine serum albumin (Sigma, St. Louis MO). The presence of MAb 11E10 within the cells was detected with Alexa Fluor 488-labeled donkey anti-mouse IgG (Invitrogen, Carlsbad, CA). Total Stx2 within the intoxicated cells was labeled with rabbit anti-Stx2 PAb, and Alexa Fluor 488-conjugated donkey anti-rabbit IgG was used as the secondary antibody (Invitrogen, Carlsbad, CA). Stx2 and endosome double labeling was accomplished with anti-Stx2 MAb 11F11 (BEI Resources, Manassas, VA) and anti-EEA1 (C-15) goat PAb (Santa Cruz Biotechnology, Santa Cruz, CA), respectively, and Alexa Fluor-labeled secondary antibodies. After incubation with the appropriate primary and secondary antibodies, the cells were fixed with formalin for 20 min at 37°C, and the slides were mounted with SlowFade medium (Invitrogen, Carlsbad, CA). Images at ϫ40 magnification of the bound fluorophore-labeled secondary antibodies were obtained via an Olympus microscope with a reflected-light fluorescence attachment and a Spot CCD digital camera (Diagnostic Instrument Products, Sterling Heights, MI). Fluorescence images were processed and overlaid with Adobe Photoshop (Adobe Systems, San Jose, CA).
RESULTS

Interaction of initial chimeric toxins with MAb 11E10.
To determine the portion of Stx2 that interacts with MAb 11E10, we constructed an initial set of six chimeric toxin operons that contained different regions of the stxA 2 gene inserted in place of the corresponding region of stxA 1 (Fig. 1A) . Western blots of purified Stx1, Stx2, or lysates from E. coli DH5␣ that express one of the six different chimeric Stx1/Stx2 toxins were probed with MAb 11E10. The antibody reacted strongly with Stx2 and the chimeric toxins that contained the amino acids from the following regions of the Stx2 A subunit: 29 to 297, 1 to 158, and 29 to 128 (Fig. 1B) . The chimeric toxin with the minimal portion of Stx2 that was still recognized by 11E10, albeit weakly, contained just 8 amino acids from StxA2, region 42 to 49.
Next, the capacity of MAb 11E10 to neutralize the toxicity of bacterial lysates that contained Stx1, Stx2, or one of the six initial chimeric toxins for Vero cells was examined. As expected, MAb 11E10 neutralized Stx2 but did not neutralize Stx1 (Fig. 1C) . However, the hybrid toxins with region 29 to 297 or 1 to 158 from StxA2 were about 85% neutralized by 11E10 compared to Stx2, a result that led to the deduction that components of the 11E10 epitope lie between residues 29 and 158 of Stx2. In contrast, the chimeric toxin with amino acids 29 to 128 from Stx2 was recognized strongly in the immunoblot (Fig. 1B, lane 5) but was only neutralized to about 32% of the level of Stx2 (Fig. 1C, bar 5 ). Together these findings suggest that the 11E10 neutralizing epitope encompasses a larger number of amino acids than are present in the Stx1(2A ) chimera. The other three chimeric toxins that were weakly detected by MAb 11E10 in the Western blot analysis were not appreciably neutralized by 11E10 (less than 15%) compared to the normalized level of Stx2 neutralization.
Analyses of differences between the Stx1 and Stx2 A subunit amino acid sequences and crystal structures. The Western blot and neutralization analyses of the first set of chimeric toxins indicated that the 11E10 epitope required at least amino acids 42 to 49 of the Stx2 A subunit for toxin detection but also revealed that additional amino acids were needed for full rec-
on October 16, 2017 by guest http://iai.asm.org/ ognition and toxin neutralization. Therefore, the amino acid sequences of the mature A subunits from Stx1 and Stx2 were aligned to identify additional unique stretches of amino acids that might be involved in recognition and neutralization of Stx2 by 11E10. Next, the crystal structures of Stx (7) and Stx2 (8) (Protein Data Bank accession no. 1RQ4, and 1R4P, respectively) were compared using the Deep View/Swiss-PDB viewer to assess the location of regions of differences between the toxins in the three-dimensional structures and the proximity of such regions to each other. A comparison of the two crystal structures showed that the region we had identified as minimally necessary for 11E10 binding, the 8 amino acids that span residues 42 to 49 in the Stx2 A subunit, was within one of three regions of amino acid dissimilarity we noted between Stx1 and Stx2. We named this segment of the StxA2 molecule region A ( Fig. 2A) . When the 8 amino acids from region A were viewed in the context of the Stx2 crystal structure, they appeared to form a major bend in the toxin structure (shown in green in Fig. 2B and C) and, in addition, were found on the outside face of Stx2, near the active site cleft around amino acid 167. A second dissimilar area between the A subunits of Stx1 and Stx2 was identified when the amino acid sequences and the crystal structures of these two toxins were compared, a segment we called region B (Fig. 2A) . Region B spans five residues in the A subunit of Stx2 ( 96 THISV 100 ), and 4 out of the 5 amino acids in this region differ between Stx1 and Stx2 ( Fig.   2A ). Although region B is approximately 50 amino acids away from region A, this portion of amino acids extends toward region A in the Stx2 crystal structure (region B is shown in dark blue in Fig. 2B ). The close proximity of region A to region B in a three-dimensional structure is even more apparent in a space-filling model (Fig. 2C) .
The third dissimilar area between the A subunits of Stx1 and Stx2, which we named region C, overlaps the furin cleavage site around residue 246 of Stx2 ( Fig. 2A) . Region C was identified not only because of amino acid sequence differences between Stx1 and Stx2 in that location, but also because comparison of the crystal structures of Stx and Stx2 indicated that region C was in spatial proximity to regions A and B. From our analyses of the Stx and Stx2 crystal structures, we concluded that regions A, B, and C cluster on the same face of Stx2, relatively near the catalytic active site (best seen in Fig. 2C ). Indeed, we found that the side chains of amino acids 46, 97, and 259 lie less than 15 Å apart from each other, well within a reasonable distance for antibody-antigen interaction (1) .
Interaction of the second-generation chimeric toxins with MAb 11E10. To determine whether regions A, B, and C were part of the 11E10 epitope, we produced a second set of chimeric toxins that contained various combinations of regions A, B, or C from Stx2 in place of the corresponding regions on Stx1 (Fig. 3A) . Next, Western blots of Stx2 or the chimeric toxins were probed with 11E10 (Fig. 3B) . MAb 11E10 detected all of (Fig. 3B ). The toxins missing region A were not detected by MAb 11E10 (Stx1 and Stx1 ϩBC), a finding that confirms that region A is an essential component of the 11E10 epitope. However, the two chimeric toxins that incorporated regions A and B (Stx1 ϩAB or Stx1 ϩABC) appeared to be more strongly detected by MAb 11E10 than chimeric toxins that included region A alone or A combined with region C (Fig. 3B) . Collectively, these results indicate that both regions A and B are important for full 11E10 recognition of the toxin. We next assayed sonic lysates of each of the five secondgeneration chimeric toxins (Fig. 3A) for in vitro neutralization by MAb 11E10. The antibody neutralized the chimeric toxin that contained regions A, B, and C (Stx1 ϩABC) to almost 70% of the level of Stx2 neutralization. In contrast, the chimeric toxins that contained only regions A and B (Stx1 ϩAB) or A and C (Stx1 ϩAC) were neutralized to about half the neutralization level of the Stx1 ϩABC chimera (Fig. 3C) . No appreciable neutralization by 11E10 was observed against the Stx1 ϩA or Stx1 ϩBC chimeric toxins (approximately 6.9 and 4.3% respectively). Since more extensive (Ͼ50%) neutralization of the chimeric toxins required regions A, B, and C from Stx2, we concluded that all three regions (A, B, and C) are necessary for neutralization by 11E10.
Western blot and in vitro neutralization assay results with Stx2 and Stx2 variants and MAb 11E10. To determine which of the Stx2 variants could be recognized and/or neutralized by 11E10, Stx2 or the Stx2 variants (Stx2c, Stx2d, Stx2d act , and Stx2e) were analyzed by Western blotting and by neutralization of activity on Vero cells (Fig. 4) . Stx2 and all of the Stx2 variants were recognized by 11E10, although Stx2e was detected to a much lesser extent (Fig. 4A) . This weak detection of Stx2e by 11E10 in the Western blot format is consistent with our previous report that 11E10 was unable to detect Stx2e-producing strains by colony blotting (21) . Stx2e has two conservative amino acid differences in region B as compared to Stx2 (AHISL rather than THISV). There are also several amino acid sequence differences immediately adjacent to region A (not shown). We speculate that these differences may be responsible for the reduced recognition of Stx2e by 11E10 on the Western blot.
When the neutralization capacity of MAb 11E10 for the Stx2 variant toxins was evaluated, we found that 11E10 neutralized all of the Stx2 variant toxins to Ն60% of the level of neutralization of Stx2 (Fig. 4B ). We were surprised at the level of neutralization observed by 11E10 of Stx2e because of the limited recognition of Stx2e by 11E10 in the Western blot format (Fig. 4B) . However, the neutralization of Stx2e by 11E10 in this study agrees with our previous result that showed that 11E10 partially neutralizes Stx2e (21) .
Immune and protective response of the Stx1 ؉ABC toxoid in mice. We next sought to ascertain whether a toxoided derivative of the Stx1 ϩABC hybrid molecule could elicit a serum-neutralizing or protective response to Stx2 in mice. Groups of mice were immunized with the chimeric toxoid or PBS as a control. Sera from five toxoid-immunized mice and five PBS-immunized mice were then evaluated for an anti-Stx1 neutralizing response. None of the sera from the PBS-immunized mice contained Stx1-neutralizing activity. As expected from previous studies, all five toxoid-immunized mice had neutralizing antibodies directed against Stx1 (27) . The mean antiStx1 neutralization titer for the serum from these five mice was 4.0 Ϯ 0.9 logs above background. Eleven of the sera from the remaining 34 toxoid-immunized mice had some neutralizing response to Stx2, while none of the sera from the 29 PBSimmunized mice exhibited any anti-Stx2 response (data not shown). Two weeks after the final boost, five negative-control mice and five toxoid-immunized mice were challenged i.p. with 10 LD 50 s of Stx1. All of the negative-control mice died, while the toxoid-immunized mice survived the lethal challenge (Table 3) , as predicted from the results of a previous study (27) . In addition, the survival of the toxoid-immunized mice that were challenged with Stx1 directly correlated with the in vitro neutralizing titers from those mice.
Because low Stx2 neutralizing antibody titers were observed in the toxoid-immunized group, we chose to challenge the rest (Table 3) , a finding that, while not statistically significant, suggests that the chimeric toxoid may have provided some protection from Stx2.
In vitro protein synthesis inhibition assay. Our finding that the 11E10 epitope appeared to consist of surface loops around the Stx2 active site cleft led us to hypothesize that 11E10 might neutralize Stx2 by blocking the capacity of the toxin to inhibit protein synthesis. Therefore, we assessed whether MAb 11E10 could neutralize the ribosome-inactivating effects of Stx2 in a rabbit reticulocyte protein synthesis assay to which luciferase mRNA was added. A concentration of toxin was chosen that decreased the signal from the luciferase reporter protein by approximately 60% as compared to the signal measured when no toxin was added (Fig. 5) . Addition of 11E10 to the assay allowed protein synthesis to occur in the rabbit reticulocyte lysate even when Stx2 was present, whereas the isotypematched irrelevant antibody did not (Fig. 5) .
MAb 11E10 alters the overall distribution of Stx2 in Vero cells. Although we found that MAb 11E10 prevented the inhibition of protein synthesis by Stx2 in the in vitro protein synthesis assay, we further hypothesized that 11E10 may prevent Stx2 from reaching ribosomes in the cytoplasm of intoxicated Vero cells. We therefore sought to determine if MAb 11E10 alters Stx2 localization in target cells. (Fig. 6 ). Stx2 appeared to be distributed throughout the cytoplasm in the absence of 11E10 (Fig. 6A ) but seemed to remain concentrated in largely perinuclear bodies in the presence of 11E10 (Fig. 6B) . When the cells incubated with the toxin-11E10 mixture were stained with antimouse IgG, 11E10 was observed in the same perinuclear punctate structures as Stx2 (Fig. 6C) . MAb 11E10 was unable to enter cells in the absence of toxin (Fig. 6D) . The localization of 11E10-bound Stx2 within punctate bodies around the nucleus suggested that the antibody/toxin complex entered the cell but did not traffic into the cytoplasm. We therefore asked if Stx2 or 11E10-bound Stx2 was localized in early endosomes by immunostaining the intoxicated cells with the early endosome marker MAb EEA-1. We found that much of the Stx2 in cells intoxicated with 11E10-bound Stx2 colocalized with the early endosome marker (Fig. 6E to G) , as shown by a yelloworange color when the staining patterns were overlapped. In contrast, when Vero cells were incubated with Stx2 alone, the toxin was found throughout the cytoplasm and only a small amount colocalized with the early endosome marker (Fig. 6H to J).
DISCUSSION
Our results demonstrate that the MAb 11E10 epitope is conformational and comprises three nonlinear regions in the Stx2 A subunit that appear close to the active site of the toxin in the crystal structure (Fig. 2C) . Our strategy to identify the 11E10 epitope involved the generation of chimeric Stx1/Stx2 toxins and was based on the assumption that placing Stx2 sequences onto the Stx1 backbone would maintain the threedimensional tertiary structure of the antibody epitope and allow recognition by MAb 11E10. We found that the minimal region of StxA2 that allowed recognition by 11E10 in Western analysis consisted of only 8 Stx2 amino acids ( 42 NHTPPGSY 49 ). However, the chimeric Stx1/Stx2 with just those 8 amino acids from Stx2 (region A) was not neutralized by MAb 11E10. Because 11E10 neutralizes Stx2, we considered that the 8 amino acids we had identified consisted of a critical region of the 11E10 epitope but did not comprise the complete neutralizing epitope. We further analyzed differences in both the amino acid sequences and crystal structures of Stx1 and Stx2 to try to identify additional regions on Stx2 that might be involved in 11E10 recognition and neutralization. Through these comparisons, we identified two more segments of Stx2 that could potentially contribute to the 11E10 epitope. Indeed, we found that all three regions were required for the most complete recognition and neutralization by 11E10 when those regions were used to replace the corresponding segments on Stx1.
Our conclusion that the complete 11E10 neutralizing epitope comprises three noncontinuous regions on Stx2 is perhaps surprising because the MAb recognizes Stx2 under the putatively denaturing conditions of a Western blot. Several explanations for this latter observation are conceivable. These possibilities include that the Western reactivity is primarily due to the interaction of 11E10 with region A ( 42 NHTPPGSY 49 ) or that partial refolding of the A subunit occurs during the Western blot process, as we observed for MAb 13C4 in another study (26) .
The sequences of the three surface loops that form the MAb 6 . MAb 11E10 alters the overall cellular distribution of Stx2 in Vero cells. Stx2 was mixed with PBS (A and H to J) or 11E10 (B, C, and E to G) and then added to Vero cells for 6 h. As a control, 11E10 was added to Vero cells in the absence of Stx2 (D). The toxin was detected with PAb against Stx2 followed by secondary antibody conjugated with Alexa Fluor 488 (A and B), while 11E10 was detected with anti-mouse IgG conjugated with Alexa Fluor 488 (C and D). Stx2 colocalization with the early endosome marker EEA1 was assessed by double labeling of intoxicated cells. Stx2 distribution in the presence (E) and absence (H) of antibody 11E10 was visualized with anti-Stx2 MAb 11F11 and green fluorescent secondary antibody. The distribution of endosome marker EEA1 was visualized with goat anti-EEA1 and red fluorescent secondary antibodies (F and I). These staining patterns were superimposed (G and J), and colocalization of toxin with endosomes was indicated by a yellow-orange coloration. compared to Stx2 may indicate that the sequences in region B that are different between Stx2 and Stx2e are more important for recognition on Western blotting than for neutralization. However, the fact that 11E10 has the capacity to neutralize all of these variant toxins suggests that it may be a good candidate for treating disease mediated by Stx2 and Stx2-related toxins in humans. Indeed, we have found that 11E10 is protective in a toxemia (Stx2) model of disease (25) and an orally fed mouse model of disease with a strain that produces Stx2d act (4) . We are currently involved in an ongoing laboratory evaluation of the humanized version of 11E10, c␣Stx2, on which phase I safety testing has been completed (3). We attempted to protect mice from Stx2 challenge by immunization with the toxoided chimeric Stx1 molecule that contained just the 29 amino acids from Stx2 that comprise the 11E10 epitope. We found that although the immunized mice raised a protective response to Stx1, only a few of the mice generated Stx2-neutralizing antibodies, and these were of low titer. The response to Stx2 may have been improved with additional boosts of the chimeric toxoid. However, it is more likely that protecting the mice from Stx2 with the 11E10 epitope in the context of the Stx1 toxoid was an unrealistic expectation given the small percentage of that hybrid molecule that actually represented Stx2.
We found that 11E10 blocked the enzymatic activity of Stx2 in vitro, a fact that we predicted based on the close proximity of the 11E10 epitope to the toxin active site. We further observed that 11E10 altered the overall distribution of the toxin inside the cell, a finding that is similar to the data on Stx2 neutralization by a different StxA2 MAb, 5C12, as reported by Krautz-Peterson et al. (11) . These investigators concluded that when MAb 5C12 binds StxA2 it alters the intracellular trafficking pattern of the toxin (11) . Our data indicate that once the 11E10/Stx2 complex binds to and enters the host cell, the antibody may prevent toxin trafficking to the target ribosomes in the cytosol. However, since we demonstrated that 11E10 prevented the enzymatic function of the toxin in vitro, we predict that should the A subunit of Stx2 complexed with 11E10 reach its enzymatic target in the cytosol, the toxin would be unable to kill the cell.
